US2020390761A1PendingUtilityA1

Treating cancer with atr inhibitors

65
Assignee: VERTEX PHARMAPriority: Sep 30, 2011Filed: Aug 26, 2020Published: Dec 17, 2020
Est. expirySep 30, 2031(~5.2 yrs left)· nominal 20-yr term from priority
Inventors:John Robert PollardPhilip Michael Reaper
A61K 31/505A61K 31/506A61K 33/243A61P 35/00A61K 31/497A61K 31/555A61N 2005/1098A61K 31/4965A61P 1/18A61K 31/7048A61K 2121/00A61K 31/7068A61P 43/00A61K 45/06A61K 33/24
65
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

This invention relates to methods and compositions for treating pancreatic cancer. More specifically, this invention relates to treating pancreatic cancer with certain ATR inhibitors in combination with gemcitabine and/or radiation therapy. This invention also relates to methods and compositions for treating non-small cell lung cancer. More specifically, this invention relates to treating non-small cell lung cancer with an ATR inhibitor in combination with cisplatin or carboplatin, etoposide, and ionizing radiation.

Claims

exact text as granted — not AI-modified
1 - 22 . (canceled) 
     
     
         23 . A method for treatment of pancreatic cancer in a patient, comprising administering to the patient in need thereof an effective amount of a compound of formula 822: 
       
         
           
           
               
               
           
         
         in combination with gemcitabine, radiation, or gemcitabine and radiation. 
       
     
     
         24 . The method of  claim 23 , wherein the treatment with the compound is in combination with gemcitabine. 
     
     
         25 . The method of  claim 23 , wherein the treatment with the compound in in combination with radiation. 
     
     
         26 . The method of  claim 23 , wherein the treatment with the compound in combination with gemcitabine and radiation. 
     
     
         27 . A method of killing hypoxic pancreatic cancer cells in a patient, comprising administering to a patient in need thereof an effective amount of a compound of formula 822: 
       
         
           
           
               
               
           
         
         in combination with gemcitabine, radiation, or gemcitabine and radiation. 
       
     
     
         28 . The method of  claim 27 , wherein the compound is administered in combination with gemcitabine. 
     
     
         29 . The method of  claim 27 , wherein the compound is administered in combination with radiation. 
     
     
         30 . The method of  claim 27 , wherein the compound is administered in combination with gemcitabine and radiation. 
     
     
         31 . The method of  claim 27 , wherein the hypoxic pancreatic cancer cells display resistance to gemcitabine or radiation.

Join the waitlist — get patent alerts

Track US2020390761A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.